Search

Displaying results 3581 - 3590 of 4236 in total
  1. Drug

    Lixmabegagene relduparvovec

    go.drugbank.com/drugs/DB16816
    Investigational

    Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1).

  2. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  3. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common

  4. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.

  5. Drug

    Metribolone

    go.drugbank.com/drugs/DB02998
    Experimental

    It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

  6. Drug

    MK-4541

    go.drugbank.com/drugs/DB17016
    Experimental

    MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.[A252687]

  7. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.

  8. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  9. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.

  10. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome